Ag85B-ESAT6 fusion protein H1 + Ag85B-ESAT6 fusion protein H1 + Ag85B-ESAT6 fusion protein H1 + Ag85B-ESAT6 fusion protein H1 + Ag85B-ESAT6 fusion protein H1 + Ag85B-ESAT6 fusion protein H1
Phase 1Terminated 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Tuberculosis
Conditions
Tuberculosis
Trial Timeline
Jan 1, 2007 → Feb 1, 2008
NCT ID
NCT00440544About Ag85B-ESAT6 fusion protein H1 + Ag85B-ESAT6 fusion protein H1 + Ag85B-ESAT6 fusion protein H1 + Ag85B-ESAT6 fusion protein H1 + Ag85B-ESAT6 fusion protein H1 + Ag85B-ESAT6 fusion protein H1
Ag85B-ESAT6 fusion protein H1 + Ag85B-ESAT6 fusion protein H1 + Ag85B-ESAT6 fusion protein H1 + Ag85B-ESAT6 fusion protein H1 + Ag85B-ESAT6 fusion protein H1 + Ag85B-ESAT6 fusion protein H1 is a phase 1 stage product being developed by Novartis for Tuberculosis. The current trial status is terminated. This product is registered under clinical trial identifier NCT00440544. Target conditions include Tuberculosis.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00440544 | Phase 1 | Terminated |
Competing Products
20 competing products in Tuberculosis